CA Patent

CA3088401A1 — Dosing regimen for missed doses for long-acting injectable paliperidone esters

Assigned to Janssen Pharmaceutica NV · Expires 2016-10-07 · 10y expired

What this patent protects

The present application provides paliperidone palmitate for use in patients who have missed a treatment of 3-month paliperidone palmitate extended-release injectable suspension formulation and related methods

USPTO Abstract

The present application provides paliperidone palmitate for use in patients who have missed a treatment of 3-month paliperidone palmitate extended-release injectable suspension formulation and related methods

Drugs covered by this patent

Patent Metadata

Patent number
CA3088401A1
Jurisdiction
CA
Classification
—
Expires
2016-10-07
Drug substance claim
No
Drug product claim
No
Assignee
Janssen Pharmaceutica NV
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.